Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

335P - PD-L1 profile of nasopharyngeal cancer patients in Indonesia

Date

23 Nov 2019

Session

Poster display session

Topics

Immunotherapy

Tumour Site

Presenters

Handoko Handoko

Citation

Annals of Oncology (2019) 30 (suppl_9): ix107-ix114. 10.1093/annonc/mdz438

Authors

H. Handoko1, S.A. Gondhowiardjo1, M. Adham2, L. Lisnawati3, D.L. Tobing4, H. Kodrat1, I.M. Haryoga1, A.G. Dwiyono1, Y.A. Kristian1, T.B. Mayang Permata1

Author affiliations

  • 1 Radiotherapy Department, Faculty of Medicine University of Indonesia, 10430 - Central Jakarta/ID
  • 2 Ent Department, Faculty of Medicine University of Indonesia, 10430 - Central Jakarta/ID
  • 3 Anatomical Pathology Department, Faculty of Medicine University of Indonesia, 10430 - Central Jakarta/ID
  • 4 Clinical Pathology Department, Dharmais Cancer Hospital, 11420 - Central Jakarta/ID

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 335P

Background

Molecular and biological characterization of nasopharyngeal cancer (NPC) is scarce. Clinical trials of emerging treatment such as immunotherapy for NPC in endemic area is lacking. Currently the most extensively studied immune related molecule that potentially become the target for treatment is PD-1/PD-L1. PD-L1 profile of NPC patients in Indonesia has never been studied before. This study aimed to elucidate PD-L1 profile from NPC specimens in Indonesia.

Methods

Nasopharyngeal biopsy specimen was taken for PD-L1 protein examination with enzyme-linked immunosorbent assay (ELISA) method. Tissue specimen was homogenized and then ELISA test was conducted using ABCAM AB214565 kit. All protocols from the manufacturer kit was followed. Total protein concentration from homogenized tissue specimen was obtained through Bradford protein assay method. Then, PD-L1 concentration per mg protein of tissue specimen was calculated.

Results

Twenty-four nasopharyngeal biopsy specimens was obtained. The average age of all patients was 45 years old. Sixteen (66.67%) out of 24 specimens were confirmed histologically to be undifferentiated nasopharyngeal carcinoma. The rest, 8 other specimens have normal histology. Average PD-L1 concentration from NPC specimens was 2,186.67 ± 1,399.32 pg/mg protein (Range: 461.76 to 4,805.85 pg/mg protein). Average PD-L1 concentration from non NPC specimens was 612.43 ± 314.04 pg/mg protein (Range: 326.87 to 1,155.19 pg/mg protein).

Conclusions

From this preliminary result, PD-L1 protein (both in tumor cells and in immune cells) from NPC specimens has been shown to be elevated compared to normal nasopharyngeal epithelium. This finding indicate that further work is warranted to test anti PD-L1 drug for NPC patients that has failed all the standard treatment. Furthermore, our upcoming work would be exploring relationship between PD-L1, EBV, and tumor microenvironment from our NPC specimens.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

University of Indonesia.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.